LATEST PRESS RELEASES

27 views16 min read

Cybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin
- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression Rating Scale ("MADRS") score reduction from baseline between CYB003 (12mg) vs. placebo (p= 0.0005) -- For reference, pooled data from 232... Read More...
534 views8 min read

Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 31, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is... Read More...
574 views6 min read

Psyence Production Expands Capability

Psyence Group
TORONTO, Oct. 30, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin ... Read More...
CalendarFinancials40 views3 min read

COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023

COMPASS Pathways plc
COMPASS PathwaysLONDON, Oct. 24, 2023 -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2023, and provide an update on recent business developments on November 2... Read More...
M & A36 views12 min read

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Cybin
This news release constitutes a "designated news release" for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to its short form base shelf prospectus dated August 17, 2023.- Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest ... Read More...
13 views0 min read

Mydecine Innovations Group gearing up for human trials after completing Aquis listing

Mydecine Innovations Group
London, UK --News Direct-- Mydecine Innovations Group Inc Mydecine Innovations Group Inc (OTC:MYCOF, NEO:MYCO) CEO Joshua Bartch speaks to Thomas Warner from Proactive London about the biotechnology company's ambitious goals in the psychedelic medicine sector.Bartch explains that Mydecine focuses on developing "second generation" drugs de... Read More...
17 views4 min read

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Revive Therapeutics
Revive Therapeutics Ltd.TORONTO, Oct. 11, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophil... Read More...
602 views7 min read

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 10, 2023 -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD... Read More...
501 views4 min read

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 05, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to ... Read More...
Calendar194 views4 min read

Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

Mydecine Innovations Group
VANCOUVER, British Columbia, Sept. 27, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...
263 views6 min read

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

Cybin
TORONTO, September 26, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced an agreement with Fluence, a leading continuing... Read More...
444 views4 min read

Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

Mydecine Innovations Group
VANCOUVER, British Columbia, Sept. 20, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased t... Read More...
176 views3 min read

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Silo Pharma
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on posi... Read More...
868 views4 min read

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

Mydecine Innovations Group
VANCOUVER, British Columbia, Sept. 19, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...
1442 views4 min read

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

Numinus Wellness
The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...
Calendar79 views4 min read

BetterLife Pharma to Host Investors Update Call on September 18, 2023

BetterLife Pharma
BetterLife Pharma Inc.VANCOUVER, British Columbia, Sept. 14, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an invest... Read More...
2831 views4 min read

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Optimi Health
VANCOUVER, British Columbia, Sept. 14, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Compan... Read More...
32 views4 min read

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program

Optimi Health
Optimi Health Corp.VANCOUVER, British Columbia, Sept. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers Optimi to embark on the f... Read More...
55 views4 min read

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

PharmaTher Holdings
TORONTO, Sept. 06, 2023 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has submitted a priority original Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FD... Read More...
29 views7 min read

Red Light Holland Submits Permit Application to the Township of Cavan-Monaghan for the Company’s 65,000 Square Foot Mushroom Farm

Red Light Holland
Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin t... Read More...
Capital Raise47 views3 min read

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health
VANCOUVER, British Columbia, Sept. 05, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it... Read More...
M & A142 views18 min read

Cybin to Acquire Small Pharma Inc.

Cybin
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT pr... Read More...
113 views7 min read

Red Light Holland Psilocybin Microdosing Capsules Aimed To Be Distributed by Nubu Pharmaceuticals In Australia Pass 8 Weeks of Stability Testing By CCREST Laboratories

Red Light Holland
Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of the first completed stability tests for the capsules, confirming stability of psilocybinConfirmation of stability of psilocybin follows the previously announced complet... Read More...
145 views4 min read

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics
TORONTO, Aug. 22, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of... Read More...
Capital Raise667 views4 min read

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Psyence Group
TORONTO, Aug. 21, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.... Read More...
Financials1271 views11 min read

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Mydecine Innovations Group
VANCOUVER, British Columbia, Aug. 14, 2023 -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six ... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!